For heavily pretreated HER2-mutant NSCLC, a phase I study showed that the ORR of T-DXd was 72.7%, and the median PFS was 11.3 months (95% CI, 8.1–14.3) (32). Here, ERBB2 is linked to non-small cell lung carcinoma.